Enterprise Value

10.71B

Cash

1.861B

Avg Qtr Burn

-122.2M

Short % of Float

5.17%

Insider Ownership

4.25%

Institutional Own.

88.09%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Big Mover™

Susp. Mover™

Phase 4

Data readout

ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Approved

Quarterly sales

EXONDYS 51 (eteplirsen) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

VYONDYS 53 (golodirsen) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Phase 3

Update

SRP-5051 Details
Duchenne muscular dystrophy

Phase 2

Data readout

SRP-6004 Details
Limb-Girdle Muscular Dystrophy, Dysferlinopathy

Phase 1

Data readout

Phase 1

Update